Table 2.
Treatment differences among different cohorts
| Treatment variables | Number of subjects | Entire cohort |
United States |
United Kingdom |
Europe |
P value |
|---|---|---|---|---|---|---|
| n = 191 | n = 44 | n = 83 | n = 64 | |||
| Use of pulse steroids, n (%) | 117 (61) | 35 (80) | 44 (53) | 38 (59) | 0.013 | |
| Cumulative dose of i.v. pulse methylprednisolone (mg) | Mean (SD) | 930 (981); n = 175 | 1658 (1243); n = 43 | 730 (755); n = 74 | 647 (733); n = 58 | <0.001 |
| Cumulative steroid dose for remission induction (mg) | Mean (SD) | 2962 (1841); n = 171 | 4153 (2427); n = 35 | 2174 (1229); n = 83 | 3408 (1642); n = 53 | <0.001 |
| Daily prednisone dose at 16 wk (mg) | Mean (SD) | 8.27 (6.51); n = 174 | 8.85 (6.94); n = 36 | 7.39 (5.1); n = 80 | 9.14 (7.79); n = 58 | 0.2487 |
| Daily prednisone dose at 6 mo (mg) | Mean (SD) | 5.10 (4.43); n = 171 | 4.02 (3.70); n = 35 | 5.24 (3.73); n = 75 | 5.57 (5.47); n = 61 | 0.2463 |
| Proportion off steroids at 6 mo, n (%) | 46 (26); n = 178 | 14 (36); n = 39 | 16 (21); n = 77 | 16 (26); n = 62 | 0.214 | |
| Rituximab use only, n (%) | (n = 191) | 84 (44) | 28 (64) | 28 (34) | 28 (44) | 0.005 |
| Dosing of rituximab, n (%)a | 1 g every 2 wk for 2 doses | 100 (75); n = 133 | 22 (58); n = 38 | 43 (77); n = 56 | 35 (90); n = 39 | 0.036 |
| 375 mg/m2 once weekly for 4 wk | 31 (23); n = 133 | 14 (37); n = 38 | 13 (23); n = 56 | 4 (10); n = 39 | ||
| Single 1-g dose | 1 (1); n = 133 | 1 (3); n = 38 | 0; n = 56 | 0; n = 39 | ||
| Single 500-mg dose | 1 (1); n = 133 | 1 (3); n = 38 | 0; n = 56 | 0; n = 39 | ||
| Cyclophosphamide use only, n (%) | (n = 191) | 49 (26) | 5 (11) | 23 (28) | 21 (33) | 0.037 |
| Rituximab and cyclophosphamide, n (%) | (n = 191) | 49 (26) | 10 (23) | 28 (34) | 11 (17) | 0.066 |
| Cyclophosphamide cumulative dose in grams | Mean (SD) | 3.4 (2.6); n = 95 | 4.9 (4); n = 15 | 3 (2.4); n = 51 | 3.5 (1.9); n = 29 | 0.047 |
| Cyclophosphamide route of administration, n (%) | Oral | 10 (10); n = 98 | 5 (33); n = 15 | 4 (8); n = 51 | 1 (3); n = 32 | 0.002 |
| IV | 84 (86); n = 98 | 8 (53); n = 15 | 45 (88); n = 51 | 31 (97); n = 32 | ||
| Both | 4 (4); n = 98 | 2 (13); n = 15 | 2 (4); n = 51 | 0; n = 32 | ||
| PLEX, n (%) | n = 191 | 26 (14) | 8 (18) | 13 (16) | 5 (8) | 0.234 |
| Use of hydroxychloroquine | n = 188 | 1 (1); n = 188 | 0; n = 42 | 0; n = 82 | 1 (2); n = 64 | 0.378 |
| Use of PJP prophylaxis | n = 191 | 162 (84) | 36 (82) | 80 (96) | 46 (72) | <0.001 |
| i.v.Ig | n = 191 | 5 (3) | 3 (7) | 1 (1) | 1 (2) | 0.137 |
| MMF | n = 191 | 6 (3) | 2 (5) | 2 (2) | 2 (3) | 0.4375 |
| Tocilizumab | n = 191 | 1 (1) | 0 | 0 | 1 (2) | 0.369 |
| MTX use | n = 191 | 1 (1) | 0 | 1 (1) | 0 | 0.52 |
| Avacopan | n = 191 | 1 (1) | 0 | 1 (1) | 0 | 0.52 |
MMF, Mycophenolate mofetil; MTX, methotrexate; PJP, Pneumocystis Jiroveci pneumonia; PLEX, plasma exchange.
a
Proportions are calculated with the denominator including all patients on rituximab (patients receiving rituximab alone or combined rituximab and cyclophosphamide therapy).